Edition:
India

VistaGen Therapeutics Inc (VTGN.OQ)

VTGN.OQ on NASDAQ Stock Exchange Capital Market

1.31USD
22 Jun 2018
Change (% chg)

$-0.06 (-4.38%)
Prev Close
$1.37
Open
$1.36
Day's High
$1.36
Day's Low
$1.28
Volume
94,480
Avg. Vol
123,285
52-wk High
$2.65
52-wk Low
$0.69

Latest Key Developments (Source: Significant Developments)

Vistagen Therapeutics Receives FDA Fast Track Designation For Av-101 For Treatment Of Major Depressive Disorder
Wednesday, 3 Jan 2018 

Jan 3 (Reuters) - Vistagen Therapeutics Inc ::VISTAGEN THERAPEUTICS RECEIVES FDA FAST TRACK DESIGNATION FOR AV-101 FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER.VISTAGEN THERAPEUTICS INC - ‍ON TRACK TO DOSE FIRST PATIENT IN AV-101 PHASE 2 MDD ADJUNCTIVE TREATMENT STUDY IN Q1 OF 2018​.  Full Article

Intracoastal Capital Llc Reports A 9.99 Pct Passive Stake In Vistagen Therapeutics As Of Dec 13
Thursday, 21 Dec 2017 

Dec 20 (Reuters) - Intracoastal Capital Llc::REPORTS a 9.99 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC <<>>: AS OF DEC 13 - SEC FILING.  Full Article

Sabby Management LLC Reports A 9.15 Pct Passive Stake In Vistagen Therapeutics
Thursday, 14 Dec 2017 

Dec 14 (Reuters) - Vistagen Therapeutics Inc ::SABBY MANAGEMENT LLC REPORTS A 9.15 PCT PASSIVE STAKE IN VISTAGEN THERAPEUTICS INC <<>> AS OF DEC 11 - SEC FILING.  Full Article

Vistagen Therapeutics posts Q2 loss of $0.53 per share
Friday, 10 Nov 2017 

Nov 9 (Reuters) - Vistagen Therapeutics Inc :Vistagen therapeutics reports second fiscal quarter 2018 financial results and provides business update.Qtrly ‍basic and diluted net loss attributable to common stockholders per common share​ of $0.53.  Full Article

VistaGen Therapeutics files for offering of up to $23 mln of common stock
Thursday, 19 Oct 2017 

Oct 19 (Reuters) - VistaGen Therapeutics Inc :VistaGen Therapeutics Inc files for offering of up to $23 million of common stock – SEC filing‍​.  Full Article

VistaGen Therapeutics reports Q3 loss per share $0.34
Tuesday, 14 Feb 2017 

VistaGen Therapeutics Inc : VistaGen Therapeutics reports fiscal third quarter 2017 financial results and provides corporate update .Q3 loss per share $0.34.  Full Article

Vistagen Therapeutics provides business outlook
Thursday, 22 Sep 2016 

Vistagen Therapeutics Inc : Vistagen Therapeutics provides business outlook and sets corporate milestones . Says Vistagen expects to report topline data from its NIMH-sponsored Phase 2a study in Q2 of 2017 . Expects to receive FDA fast track designation for AV-101 as adjunctive treatment for MDD during first half of 2017. .Company anticipates topline results for AV-101 from Phase 2b study to be reported in Q3 of 2018.  Full Article